Business
Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s Disease
Findings support Aβ vaccine candidate consisting of conformational B cell epitope of Aβ oligomers conjugated to a carrier protein as a potential strategy for
About this update from Promis Neurosciences Inc.
[{"type":"text","content":"Findings support Aβ vaccine candidate consisting of conformational B cell epitope of Aβ oligomers conjugated to a carrier protein as a potential strategy for preventing Alzheimer’s disease progression TORONTO, Ontario and CAMBRIDGE, Massachusetts, April 25, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today presented preclinical data supporting the development of a computationally-derived amyloid-beta (Aβ) vaccine for AD at the American Academy of Neurology (AAN) 2023 Annual Meeting. The Company believes that a vaccination strategy for the prevention or treatment of AD, compared to passive immunization with a therapeutic antibody, could present several potential advantages, including the potential for sustained anti-disease activity and ease of use for prevention in conjunction with diagnostic biomarkers, and fewer doses compared with chronic antibody treatment. An AD vaccine capable of inducing an effective antibody response against pathogenic Aβ could potentially be administered as a preemptive measure to at-risk individuals to prevent the symptomatic disease or given therapeutically to diagnosed patients to inhibit the progression of AD. Using computational modeling, ProMIS has identified conformational epitopes that are exposed on misfolded, toxic Aβ oligomers (AβO), the driver of disease, and not on monomers or plaque. In mouse preclinical studies, vaccination with a conformational AβO epitope conjugated to a carrier protein and delivered with adjuvant induced a strong, sustained antibody response with the desired oligomer selectivity. “These encouraging data support our approach of immunization with a rationally designed vaccine consisting of an Aβ oligomer conformational B cell epitope conjugated to a carrier protein,” said Johanne Kaplan, Ph.D., Chief Development Officer of ProMIS Neurosciences and first author of the presentation. “We look forward to advancing our goal of developing a safe and effective AD vaccine to induce a specific immune response against toxic Aβ oligomers.” In an oral presentation titled, “Rational design of a ...